Replies to post #33534 on Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

We conclude that VIP infusion reversed existing tubulointerstitial fibrosis suggesting a possible therapeutic role for a VIP based therapy in chronic kidney disease.

https://www.sciencedirect.com/science/article/pii/S0014299920300716

Tubulointerstitial renal fibrosis, characterized as a progressive detrimental connective tissue deposition on the kidney parenchyma, appears to be a harmful process leading inevitably to renal function deterioration, independently of the primary renal disease which causes the original kidney injury.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2776335/

[whosjohngalt]

amazing

the possibilities, seems endless.

best

[cfoofme]

I wonder if VIP has been trialed for pulmonary fibrosis. A close friend is suffering with that deadly disease and has been told he has 1-3 years to live.